Acrivon Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 28, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Power of Attorney (included on signature page)
SIGNAT URES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Acrivon Therapeutics, Inc. | ||
| Date: March 28, 2024 | By: | /s/ Peter Blume-Jensen |
|---|---|---|
| Peter Blume-Jensen, M.D., Ph.D. | ||
| Chief Executive Officer and President | ||
| Date: March 28, 2024 | By: | /s/ Rasmus Holm-Jorgensen |
| Rasmus Holm-Jorgensen | ||
| Chief Financial Officer | ||
POWER OF ATTORNEY
KNOW ALL BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Peter Blume-Jensen and Rasmus Holm-Jorgensen, and each of them, as his or her true and lawful agents, proxies and attorneys-in-fact, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Peter Blume-Jensen | Chief Executive Officer, President and Chairman of the Board | March 28, 2024 |
| Peter Blume-Jensen, M.D., Ph.D. | (Principal Executive Officer) | |
| /s/ Rasmus Holm-Jorgensen | Chief Financial Officer | March 28, 2024 |
| Rasmus Holm-Jorgensen | (Principal Financial and Accounting Officer) | |
| /s/ Derek DiRocco | Director | March 28, 2024 |
| Derek DiRocco, Ph.D. | ||
| /s/ Kristina Masson | Executive Vice President, Business Operations, Director | March 28, 2024 |
| Kristina Masson, Ph.D., M.B.A. | ||
| /s/ Sharon Shacham | Director | March 28, 2024 |
| Sharon Shacham, Ph.D., M.B.A. | ||
| /s/ Michael Tomsicek | Director | March 28, 2024 |
| Michael Tomsicek, M.B.A. | ||
| /s/ Charles Baum | Director | March 28, 2024 |
| Charles Baum, M.D., Ph.D. | ||
| /s/ Ivana Magovcevic-Liebisch | Director | March 28, 2024 |
| Ivana Magovcevic-Liebisch, Ph.D., J.D. | ||
| /s/ Santhosh Palani | Director | March 28, 2024 |
|---|---|---|
| Santhosh Palani, Ph.D., C. F.A. | ||
INDEX TO THE CONSOLIDATED FINANCIAL STATEMENTS
Consolidated Financial Statements for the Years Ended December 31, 2023 and 2022:
| Report of Independent Registered Public Accounting Firm – PCAOB ID No. 238 | F-2 |
|---|---|
| Consolidated Balance Sheets | F-3 |
| Consolidated Statements of Operations and Comprehensive Loss | F-4 |
| Consolidated Statements of Convertible Preferred Stock and Stockholders’ Equity (Deficit) | F-5 |
| Consolidated Statements of Cash Flows | F-6 |
| Notes to the Consolidated Financial Statements | F-7 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.